Effects of Overexpression of the Egyptian Fruit Bat Innate Immune Genes on Filovirus Infections in the Host Cells

Ivan V. Kuzmin1,2, Palaniappan Ramanathan1,2, Christopher F. Basler3, Alexander Bukreyev1,2,4,*

1Department of Pathology, University of Texas Medical Branch, Galveston, TX, United States
2Galveston National Laboratory, Galveston, TX, United States
3Center for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, United States
4Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States

Abstract

Bats constitute a large and diverse group of mammals with unique characteristics. One of these is the ability of bats to maintain various pathogens, particularly viruses, without evidence of disease. The innate immune system has been implicated as one of the important components involved in this process. However, in contrast to the human innate immune system, little data is available for bats. In the present study we generated 23 fusion constructs of innate immune genes of Egyptian fruit bat (Rousettus aegyptiacus) with mCherry as a fluorescent reporter. We evaluated the effects of overexpressing these genes on the replication of Marburg and Ebola viruses in the Egyptian fruit bat cell line R06EJ. Both viruses were substantially inhibited by overexpression of type I, II and III interferons, as well as by DDX58 (RIG-I), IFIH1, and IRF1. Our observations suggest that the broad antiviral activity of these genes reported previously in human cells is conserved in Egyptian fruit bats and these possess anti-filovirus activities that may contribute to the efficient virus clearance.

Keywords

BAT; innate immune response; innate immune system; Egyptian fruit bat; Rousettus aegyptiacus; Ebola virus; Marburg virus; filovirus

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correspondence: Alexander Bukreyev, alexander.bukreyev@utmb.edu.

AUTHOR CONTRIBUTIONS
AB and CB: study proposition and funding acquisition. AB and IK: conceptualization, initial design, and writing. IK and PR: investigation. IK: formal analysis. AB: resources. All authors read and approved the manuscript.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
INTRODUCTION

Marburg virus (MARV) and Ebola virus (EBOV), members of the family Filoviridae, cause severe disease with high case fatality rates in humans (1). Egyptian fruit bats (Rousettus aegyptiacus) have been identified as natural reservoir hosts of MARV (2–4). Several other divergent filoviruses were detected in bats of other species, including Lloviu virus (5), Reston virus (6), Bombali virus (7), Mengla virus (8). Although anecdotal findings of EBOV genetic material in bats was reported (9), this has not been corroborated despite the extensive surveillance. Egyptian fruit bats survive infection with MARV and EBOV without apparent clinical signs (4, 10, 11). Bats of other species exhibit subclinical infections and survive infections with henipaviruses and coronaviruses that cause severe diseases in humans (12–14). Many factors have been suggested to play a role in the resistance to disease in bats, with major attention given to their immune system and relatively reduced inflammatory responses (15–18).

Indeed, bats are very diverse with more than 1,400 species described, and the same great diversity might be expected to be seen in their adaptation to pathogens, many of which are species-specific. Nevertheless, the Egyptian fruit bat represents one of a few useful models for studying bat-pathogen interactions. These bats are easy to maintain and breed in captivity, they have relatively large body size (120–180 g) which makes them convenient for manipulations and for non-destructive sampling of excretions, cells, and tissues. Parts of the genome and transcriptome of the Egyptian fruit bat have been annotated (19–21), but more efforts are required to fully understand bat-pathogen interactions.

Among the components of mammalian immune system, type I interferon (IFN) response represent the first barrier to virus infection. Triggered by cellular pathogen-sensing receptors, it leads to activation of hundreds of so-called interferon-stimulated genes (ISGs) which engage in various mechanisms of virus elimination (22–24). Type II IFN is an important activator of macrophages and inducer of class I major histocompatibility complex (25, 26) which also plays a role in antiviral response, in part via cross-talk with the type I IFN pathway (26, 27). Type III IFNs are distributed unevenly in tissues and organs of different animals, and their roles in bat immunity have been studied minimally (28, 29). A few studies addressing antiviral response of Egyptian fruit bats to filoviruses provided diverse results (30–32) suggesting that more work in this area is required.

During the recent years, substantial efforts have been undertaken to decipher the role of human ISGs in response to different viruses via screening of large panels of ISGs overexpressed in human cells (33–36). In the present study we attempted to adapt one of these approaches to screening of a subset of IFNs and ISGs of the Egyptian fruit bat which demonstrated a differential expression in response to MARV and EBOV infections in our previous study (31).
METHODS

Cells and Viruses

Immortalized fetal cells of Egyptian fruit bats, R06EJ (37), kindly provided by Dr. Ingo Jordan (ProBioGen, Berlin, Germany) were maintained in DMEM F-12 GlutaMAX medium supplemented with 10% fetal bovine serum and antibiotic/antimycotic mix (Thermo Fisher Scientific).

The recombinant Marburg virus (MARV) of bat origin (38) expressing enhanced green fluorescent protein (eGFP) was recovered using the MARV reverse genetics systems provided by Drs. Jonathan Towner, Cesar Albarino, and Stuart Nichol (CDC). The recombinant Ebola virus (EBOV) strain Mayinga (39) expressing eGFP was recovered using the EBOV reverse genetics system including the full-length clone provided by Drs. Jonathan Towner and Stuart Nichol and the EBOV NP, VP35, L, VP30, and T7 polymerase plasmids provided by Drs. Yoshihiro Kawaoka (University of Wisconsin) and Heinz Feldmann (NIH). Both viruses were passaged 3 times in Vero E6 cells.

Construction of Expression Vectors for Bat Innate Immune Genes

The mRNA sequences of the selected genes were retrieved from GenBank and amplified via nested RT-PCR from R06EJ cells or from liver and spleen tissues of healthy Egyptian fruit bats, with primer-derived removal of stop codons and ad hoc addition of restriction sites. The amplicons were inserted under control of the chicken β-actin promoter into pCAGGS/MCS vector expressing mCherry with flexible linker upstream (2 × ggtggegaggtgctca), so that mCherry was expressed in-frame with the inserted bat genes. The insertions were created either using NotI and EcoRV restriction sites or, if these sites were present in the bat genes, via seamless ligation into blunt-ended backbone using the GeneArt Seamless Cloning and Assembly kit (Thermo Fisher Scientific). For each construct, 5–10 colonies were selected for sequence verification, and clones with correct sequences were scaled-up for further studies. The empty pCAGGS/MCS vector expressing mCherry connected to the flexible linker was used as negative (mock) control.

Transfection, Infection, and Flow Cytometry

The experimental approach was similar to that described previously (35, 36). Expression plasmids were transfected into subconfluent R06EJ cells in 6-well plates using TransIT-X2 reagent (Mirus Bio LLC, Madison, WI) following manufacturers instructions. Each construct was tested in triplicates. Twenty-four h post transfection, the cells were washed with phosphate buffered saline (PBS) and infected with MARV (MOI of 1 PFU/cell, as determined in Vero E6 cells) or EBOV (MOI of 3 PFU/cell, as determined in Vero E6 cells) in the BSL-4 containment of the Galveston National Laboratory. After adsorption for one h at 37 °C, the cells were washed twice with PBS, and supplied with fresh medium. Twenty-four h post infection, the cells were removed from plates with trypsin-EDTA, washed in PBS, fixed in 4% paraformaldehyde, and subjected to flow cytometry on an Accuri C6 (BD Biosciences). From each well, 100,000–150,000 cells were counted. The results were analyzed in C6 Plus Analysis software (BD Biosciences) with a 0.1% compensation. Only mCherry+ cells were selected for comparative evaluation of the proportions of eGFP+ cells.
Whenever transfection of bat genes demonstrated an increase or decrease of infected cells compared to mock-transfected control, the experiments were repeated for corroboration of results. Statistical differences between sample triplicates were assessed by Students two-tailed unpaired $t$-test. Significance levels were set at $p \leq 0.05$.

**RESULTS**

**Selection, Sequencing and Cloning of Egyptian Fruit Bat Innate Immune Genes**

We selected a subset of innate immune genes of the Egyptian fruit bat that demonstrated the most distinct expression patterns in R06EJ cells infected with MARV and EBOV, compared to noninfected cells, in our previous study (31), Table 1. To test the antiviral effect of the genes, we attempted to adapt the system developed previously for screening of the antiviral effects of human genes in human cells (35, 36). The system we developed was based on transfection of cells with plasmids expressing bat genes of interest and a fluorescent protein mCherry, and infection of bat cells with MARV or EBOV engineered to express another fluorescent protein, eGFP (38, 39) (Figure 1, top). The levels of antiviral activities were determined by flow cytometry analysis of cells and calculation of the percentage of eGFP$^+$ (infected) cells as a percentage of mCherry$^+$ (plasmid-transfected) cells.

The empty pCAGGS/MCS vector expressing mCherry connected to the flexible linker was used as negative (mock) control. After RT-PCR amplification of bat genes, we compared all our sequences to those deposited in GenBank, and did not have discrepancies in most cases. One exception was the sequence of IFN$\alpha$ which was selected among >20 diverse clones obtained from single RT-PCR amplification. This is not surprising given that 46 type I IFNs, including 12 IFN$\alpha$ variants, were identified in the Egyptian fruit bat genome (20). We selected the sequence from the clone that most closely resembled the consensus IFN$\alpha$ sequence obtained via Sanger sequencing of the RT-PCR product, assuming that this variant predominates in the IFN$\alpha$ population. Another interesting finding was the IFIT3 sequence contained a stop codon within the expected coding region (amino acid position 346). It was present in the RT-PCR product and in all otherwise identical clones. Upon inspection of GenBank record XM_016123309, we found the same stop codon and concluded that CDS was determined and annotated in GenBank incorrectly. Therefore, we re-amplified and used in our studies a truncated version of IFIT3 consisting of 345 codons. We were unable to amplify two genes of interest, IFITM3 and IRF7, either from bat cells or organs, likely because of limited representation of the mRNA in the samples.

**Establishing the System for Screening of Bat Innate Immune Genes for the Antiviral Effect in Bat Cells**

To screen for the antiviral activity, we selected R06EJ cells because they are derived from Egyptian fruit bat, which is the natural reservoir for MARV (4), because they were more susceptible to infection with EBOV compared to another available cell line derived from the Egyptian fruit bat, RoNi7, and because they were better transfected in our previous study (31). As was observed previously by other investigators (34, 36), overexpression of various immune genes was toxic to cells, and that was the reason why we performed the study with large numbers of cells in 6-well plates (approximately 1,300,000 R06EJ cells per well),
given that over 50% of cells might be lost after transfection. Nevertheless, we had to remove from evaluation the TNFSF10 construct which was so toxic that only singular mCherry+ cells were attached to the plate 24 h after transfection. The selected transfection reagent TransIT-X2 did not demonstrate severe cytotoxicity to R06EJ cells and was reasonably efficient such that 15–30% cells were mCherry+ when the empty mCherry vector was used. The cells transfected with this vector demonstrated healthy morphology, whereas the cells transfected with most of the bat immune genes appeared rounded and in smaller sizes (Figure 1) even if they were firmly attached to the plates during all manipulations and the following observation period.

Another limiting factor of our study was the susceptibility of cells to EBOV. While the Egyptian fruit bat is the natural host of MARV, it is almost refractory to EBOV (4, 11). In fact, R06EJ cells were more susceptible to MARV (up to 15% cells were eGFP+ after infection at MOI of 1 PFU/cell) than to EBOV (about 10% cells were eGFP+ after infection at MOI of 3 PFU/cell). With all these limitations, even using the 6-well format and counting 100,000–1,500,000 cells per well at flow cytometry, we were able to detect ~1,000–5,000 mCherry+, eGFP+ cells in mock-control wells (which were considered as 100% infection in our quantitation). After optimization of the system, we chose the experimental layout which included plasmid transfection, followed by a 24 h-long incubation, infection, a 24 h-long incubation, and flow cytometry analysis (Figure 1).

The Impact of Overexpressed Bat Genes Upon Filovirus Infection

The effects of overexpressed bat genes to MARV and EBOV were similar (Figure 2). In the cells transfected with plasmids expressing type I and type II IFNs, virus replication (eGFP signal) was observed only in a small numbers of cells (Figures 1, 2). This was true not only for the mCherry+ cells but for all cells in the sample, in agreement with IFN excretion that affects bystander cells as was documented elsewhere (22–24, 26) and in our previous study (31). The type III IFN (IFNλ) had a lesser effect on the proportion of eGFP+ cells infected with MARV (50–70% reduction) but effectively suppressed replication of EBOV for over 90% (Figure 2). Overexpression of three other genes, IRF1, DDX58 (RIG-I) and IFIH1 inhibited MARV and EBOV in the transfected cells (Figure 2). Other genes overexpressed in our experiments had either no effect to the proportion of eGFP+ cells or slightly increased this proportion (IFIT1 by 6–21%; IFIT5 by 22–53%; MX2 by 11–33%; PSMA3 by 14–46; PSMA6 by 8–36%, VAMP5 by 7–34%).

DISCUSSION

The bat immune system attracts increasing scientific attention due to the ability of bats to maintain and clear various viral infections without apparent clinical signs (20, 32). Innate immune response may be an important component of such effective tolerance of pathogens.

Several large-scale studies of human innate immune genes transiently expressed in human cells and their effects to various pathogens have been published in recent years (33–36, 40). However, no such studies were published for bat immune genes at the time of submission of this manuscript. Here we amplified and sequenced 23 innate immune genes of Egyptian fruit bats, cloned them in expression plasmids, and developed a system for evaluation of
their antiviral effect against MARV and EBOV in bat cells. While bat immune system shares many key features with humans and other mammals, bats also possess so-called “unique” immune characteristics and functional differences in the regulation of their innate immune systems (28, 41–43). Therefore, direct assessment of antiviral effects of bat immune genes are of immediate importance.

We observed strong antiviral effects of overexpressed and secreted IFNs type I, II, and III against MARV and EBOV. We used fusion constructs of IFNs with mCherry, and if they are secreted, we would not observe mCherry+ cells. The observed presence of mCherry+ cells can be related to ongoing synthesis of the proteins from the transfected plasmids. Alternatively, the level of secretion may be reduced due to the fused mCherry, or mCherry is released from dead cells. The IFN effects resembled those described in human cells and are typical for mammals in general (26, 44). We overexpressed one of the 12 IFNα variants detected in the genome of Egyptian fruit bat (20). As the genome of this bat demonstrates the presence of 46 type I IFN genes (20), additional studies are required to address the effects of each of them against filoviruses and other pathogens. The type III IFN demonstrated a lesser activity against MARV than type I and type II IFNs. Type III IFNs are represented by several species which have not been annotated and characterized in the Egyptian fruit bat yet (32), and each may have its unique role in suppression of filoviruses and other pathogens. An antiviral effect of IFNλ was demonstrated, for example, against Pulau virus (family Reoviridae) in Pteropus cells (28, 29).

A broad activity of human IRF1, DDX58 (RIG-I) and IFIH1 against diverse viruses, including EBOV, was demonstrated previously in human cells (34, 36). Also, the same authors did not see substantial antiviral effects from overexpression of ISGs IFIT1–5 and MX1–2, although these genes are highly expressed in infected cells, including bat cells R06EJ (31). It is likely that these and the majority of other ISGs play their roles in the innate immune pathways but do not possess direct antiviral activity.

Interestingly, despite the very different susceptibility of Egyptian fruit bats to MARV and EBOV (4) and different mechanisms of antagonism of IFN induction and response by these viruses (45), comparison of the antiviral effects of the 23 bat immune genes demonstrated very similar profiles with equally strong activity for six of them against the two viruses.

A limitation of our study was that innate immune genes were expressed as fusion proteins, which might not function, localize, or be secreted properly. The design of our experiments did not allow us to distinguish whether overexpressed bat genes influenced virus entry or replication. Furthermore, as the observations were limited to 24 hours, and supernatants of the cultures were not tested, we did not address whether the overexpressed genes affected virus budding. That was a limitation highlighted, for example, by observations of other researchers that BST2 specifically inhibits virus budding from human cells (34, 46). In our case, BST2 did not reduce the number of eGFP+ cells, however, we do not know whether the viruses were budding efficiently and what were their concentrations in the supernatants.

Further studies are required to more completely assess the bat innate immune system. Identification and characterization of additional bat immune genes is essential. For example,
our work identified an unexpected stop codon within the proposed IFIT3 coding sequence, and some mRNAs are difficult to amplify via conventional RT-PCR which possibly suggests a polymorphism. With more data and reagents available, biological effects of bat immune system against a broad range of pathogens, and the precise role in bat IFN signaling cascades should be elucidated. Ultimately, all these studies will contribute to our understating of the protective mechanisms which allow bats to effectively control replication of many highly pathogenic viruses without an acute disease.

ACKNOWLEDGMENTS

We thank Dr. Ingo Jordan (ProBioGen, Berlin, Germany) for providing R06EJ cells, Drs. Jonathan Towner, Cezar Albarino, and Stuart Nichol (CDC, Atlanta, GA, USA) for providing MARV reverse genetics system, and Drs. Jonathan Towner, Stuart Nichol, Yoshihiro Kawaoka, and Heinz Feldmann for providing the EBOV reverse genetics system.

FUNDING

The work in part was supported by the Defense Threat Reduction Agency (DTRA), grant HDTRA1-14-1-0013 Comparative immunology of Rousettus aegyptiacus reservoir with filoviruses to CB and AB.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

REFERENCES

1. Kuhn JH, Amarasinghe GK, Perry DL. Filoviridae: Marburg and Ebola Viruses. (Lippincott-Raven Publishers: Philadelphia). (2021).
2. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog. (2009) 5:e1000536. doi: 10.1371/journal.ppat.1000536 [PubMed: 19649327]
3. Amman BR, Bird BH, Bakarr IA, Bangura J, Schuh AJ, Johnny J, et al. Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa. Nat Commun. (2020) 11:510. doi: 10.1038/s41467-020-14327-8 [PubMed: 31980636]
4. Jones ME, Schuh AJ, Amman BR, Sealy TK, Zaki SR, Nichol ST, et al. Experimental inoculation of egyptian rousette bats (Rousettus aegyptiacus) with viruses of the ebolavirus and marburgvirus genera. Viruses. (2015) 7:3420–42. doi: 10.3390/v7072779 [PubMed: 26120867]
5. Negredo A, Palacios G, Vázquez-Morón S, González F, Dopazo H, Molero F, et al. Discovery of an ebolavirus-like filovirus in Europe. PLoS Pathog. (2011) 7:e1002304. doi: 10.1371/journal.ppat.1002304 [PubMed: 22039362]
6. Jayne SJ, Field HE, de Jong C, Olival KJ, Marsh G, Tagtag AM, et al. Molecular evidence of Ebola Reston virus infection in Philippine bats. Virol J. (2015) 12:107. doi: 10.1186/s12985-015-0331-3 [PubMed: 26184657]
7. Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. (2018) 3:1084–9. doi: 10.1038/s41564-018-0227-2 [PubMed: 30150734]
8. Yang XL, Tan CW, Anderson DE, Jiang RD, Li B, Zhang W, et al. Characterization of a filovirus (Mènglà virus) from Rousettus bats in China. Nat Microbiol. (2019) 4:390–5. doi: 10.1038/s41564-018-0328-y [PubMed: 30617348]
9. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P, et al. Fruit bats as reservoirs of Ebola virus. Nature. (2005) 438:575–6. doi: 10.1038/438575a [PubMed: 16319873]
10. Paweska JT, Jansen van Vuren P, Masumu J, Leman PA, Grobbelaar AA, Birkhead M, et al. Virological and serological findings in Rousettus aegyptiacus experimentally inoculated with vero cells-adapted hogan strain of Marburg virus. PLoS ONE. (2012) 7:e45479. doi: 10.1371/journal.pone.0045479 [PubMed: 23029039]

11. Paweska JT, Storm N, Grobbelaar AA, Markotter W, Kemp A, Jansen van Vuren P. Experimental inoculation of egyptian fruit bats (rousettus aegyptiacus) with ebola virus. Viruses. (2016) 8:29. doi: 10.3390/v8020029

12. Halpin K, Hyatt AD, Fogarty R, Middleton D, Epstein JH, et al. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission. Am J Trop Med Hyg. (2011) 85:946–51. doi: 10.4269/ajtmh.2011.10-0567 [PubMed: 22049055]

13. Middleton DJ, Morrissy CJ, van der Heide BM, Russell GM, Braun MA, Westbury HA, et al. Experimental Nipah virus infection in pteropid bats (Pteropus poliocephalus). J Comp Pathol. (2007) 136:266–72. doi: 10.1016/j.jcpa.2007.03.002 [PubMed: 17498518]

14. Schlottau K, Rissmann M, Graaf A, Schön J, Sehl J, Wylezich C, et al. SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. Lancet Microbe. (2020) 1:e218–e25. doi: 10.1016/S2666-5247(20)30089-6 [PubMed: 32838346]

15. Guito JC, Prescott JB, Arnold CE, Amman BR, Schuh AJ, Spengler JR, et al. Asymptomatic infection of marburg virus reservoir bats is explained by a strategy of immunoprotective disease tolerance. Curr Biol. (2021) 31:257–70.e5. doi: 10.1016/j.cub.2020.10.015 [PubMed: 33157026]

16. Irving AT, Zhang Q, Kong PS, Luko K, Rozario P, Wen M, et al. Interferon regulatory factors IRF1 and IRF7 directly regulate gene expression in response to viral infection. Cell Rep. (2020) 33:108345. doi: 10.1016/j.celrep.2020.10.035 [PubMed: 33147460]

17. Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G. Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A. (2012) 109:4239–44. doi: 10.1073/pnas.1114981109 [PubMed: 22371602]

Front Virol. Author manuscript; available in PMC 2022 October 12.
28. Zhou P, Cowled C, Marsh GA, Shi Z, Wang LF, Baker ML. Type III IFN receptor expression and functional characterisation in the pteropid bat, Pteropus alecto. PLoS ONE. (2011) 6:e25385. doi: 10.1371/journal.pone.0025385 [PubMed: 21980438]

29. Zhou P, Cowled C, Todd S, Crameri G, Virtue ER, Marsh GA, et al. Type III IFNs in pteropid bats: differential expression patterns provide evidence for distinct roles in antiviral immunity. J Immunol. (2011) 186:3138–47. doi: 10.4049/jimmunol.1003115 [PubMed: 21278349]

30. Hölzer M, Krähling V, Amman F, Barth E, Bernhart SH, Carmelo VA, et al. Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells. Sci Rep. (2016) 6:34589. doi: 10.1038/srep34589 [PubMed: 27713552]

31. Kuzmin IV, Schwarz TM, Ilinykh PA, Jordan I, Ksiazek TG, Sachidanandam R, et al. Innate immune responses of bat and human cells to filoviruses: commonalities and distinctions. J Virol. (2017) 91:e02471–16. doi: 10.1128/JVI.02471-16 [PubMed: 28122983]

32. Arnold CE, Guito JC, Altamura LA, Lovett SP, Nagle ER, Palacios GF, et al. Transcriptomics reveal antiviral gene induction in the Egyptian rousette bat is antagonized in vitro by marburg virus infection. Viruses. (2018) 10:607. doi: 10.3390/v10110607

33. Kane M, Zang TM, Rihn SJ, Zhang F, Kueck T, Alim M, et al. Identification of interferon-stimulated genes with antiretroviral activity. Cell Host Microbe. (2016) 20:392–405. doi: 10.1016/j.chom.2016.08.005 [PubMed: 27631702]

34. Kuroda M, Halfmann PJ, Hill-Batarski L, Ozawa M, Lopes TJS, Neumann G, et al. Identification of interferon-stimulated genes that attenuate Ebola virus infection. Nat Commun. (2020) 11:2953. doi: 10.1038/s41467-020-16768-7 [PubMed: 32528005]

35. Schoggins JW, MacDuff DA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature. (2014) 505:691–5. doi: 10.1038/nature12862 [PubMed: 24284630]

36. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. (2011) 472:481–5. doi: 10.1038/nature09907 [PubMed: 21478870]

37. Jordan I, Horn D, Oehmke S, Leendertz FH, Sandig V. Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara. Virus Res. (2009) 145:54–62. doi: 10.1016/j.virusres.2009.06.007 [PubMed: 19540275]

38. Albariño CG, Wiggeton Guerrero L, Spengler JR, Uebelhoer LS, Chakrabarti AK, Nichol ST, et al. Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of Host immune responses. Virology. (2015) 476:85–91. doi: 10.1016/j.virology.2014.12.002 [PubMed: 25531184]

39. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, et al. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology. (2005) 332:20–7. doi: 10.1016/j.virol.2004.10.048 [PubMed: 15661137]

40. Li J, Ding SC, Cho H, Chung BC, Gale M Jr, Chanda SK, et al. A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response. MBio. (2013) 4:e00385–13. doi: 10.1128/mBio.00385-13 [PubMed: 23781071]

41. De La Cruz-Rivera PC, Kanchwala M, Liang C, Kumar A, Wang LF, Xing C, et al. The IFN Response in Bats Displays Distinctive IFN-Stimulated Gene Expression Kinetics with Atypical RNASEL Induction. J Immunol. (2018) 200:209–17. doi: 10.4049/jimmunol.1701214 [PubMed: 29180486]

42. Zhou P, Tachedjian M, Wynne JW, Boyd V, Cui J, Smith I, et al. Contraction of the type I IFN locus and unusual constitutive expression of IFN-α in bats. Proc Natl Acad Sci U S A. (2016) 113:2696–701. doi: 10.1073/pnas.1518240113 [PubMed: 26903655]

43. Baker ML, Schountz T, Wang LF. Antiviral immune responses of bats: a review. Zoonoses Public Health. (2013) 60:104–16. doi: 10.1111/j.1863-2378.2012.01528.x [PubMed: 23302292]

44. Stetson DB, Medzhitov R. Type I interferons in host defense. Immunity. (2006) 25:373–81. doi: 10.1016/j.immuni.2006.08.007 [PubMed: 16979569]
45. Messaoudi I, Amarasinghe GK, Basler CF. Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol. (2015) 13:663–76. doi: 10.1038/nrmicro3524 [PubMed: 26439085]

46. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A. (2009) 106:2886–91. doi: 10.1073/pnas.0811014106 [PubMed: 19179289]
FIGURE 1.
Schematic illustration of the experimental workflow. The microphotographs show cells transfected by empty mCherry plasmid (mock) and inhibitory IFNβ following infection with MARV-GFP.
FIGURE 2.
Antiviral effects of bat immune genes. (A) Flow cytometry histograms showing percentages of eGFP+ (infected) cells among mCherry+ (plasmid transfected) cells. (B) Percentages of infected (eGFP+) cells among the cells transfected with bat immune genes (mCherry+). The 100% value corresponds to the proportion of eGFP+ cells in control (mock; mCherry+ plasmid with no immune gene). Means of triplicate samples ± SD. Asterisks indicate statistical significance at 95% (*) and 99% (**). The study was performed two times which results in similar data.
Bat innate immune genes transiently overexpressed in the present study.

| Protein | Gene/protein abbreviation | Functions (abbreviated) |
|---------|---------------------------|-------------------------|
| Interferon alpha | IFNA, IFNα | Type I interferon, secreted in response to viral infection and mediates innate immune response by induction of multiple interferon-stimulated genes (ISGs) aimed to inhibit the infection by various means. |
| Interferon beta | IFNB, IFNβ | The same. |
| Interferon gamma | IFNG, IFNγ | Type II interferon, primarily secreted by specialized immune cells, promotes macrophage activation, enhances antigen presentation, coordinates lymphocyte-endothelium interaction, regulates Th1/Th2 balance, in addition, stimulates type I interferon response via circular loop. |
| Interferon lambda | IFNL, IFNλ | Type III interferon. Induces expression of ISGs and exerts antiviral properties in a similar manner to type I IFNs. In addition, to ubiquitous functioning promotes antiviral response in barrier areas such as respiratory epithelium and blood-brain barrier. |
| Interferon-induced protein with tetratricopeptide repeats 1 | IFIT1 | Specifically binds single-stranded RNA, thereby acting as a sensor of viral single-stranded RNAs and inhibiting expression of viral messenger RNAs. |
| Interferon-induced protein with tetratricopeptide repeats 2 | IFIT2 | Inhibits expression of viral messenger RNAs. Can promote apoptosis. |
| Interferon-induced protein with tetratricopeptide repeats 3 | IFIT3 | Enhances host antiviral responses by serving as an adapter bridging TBK1 to MAVS which leads to the activation of TBK1 and phosphorylation of IRF3 which translocates into nucleus to promote antiviral gene transcription. |
| Interferon-induced protein with tetratricopeptide repeats 5 | IFIT5 | Binds single-stranded RNA, thereby acting as a sensor and inhibitor of viral single-stranded RNAs. |
| Interferon-induced GTP-binding protein Mx1 | MX1 | Dynamin-like GTPase, binds and inactivates viral ribonucleocapsid. |
| Interferon-induced GTP-binding protein Mx2 | MX2 | The same, may play a role in regulating nucleocytoplasmic transport and cell-cycle progression. |
| Interferon regulatory factor 1 | IRF1 | Regulates transcription of type I interferons and ISGs in host response to viral and bacterial infections. |
| Interferon regulatory factor 9 | IRF9 | Mediates signaling by type I interferons during viral infection. |
| Antiviral innate immune response receptor RIG-I | DDX58 | Sensors cytoplasmic viral nucleic acids and activates a downstream signaling cascade leading to the production of type I interferons and proinflammatory cytokines. |
| C-X-C motif chemokine 10 | CXCL10 | Involved in a wide variety of processes such as chemotaxis, differentiation, and activation of peripheral immune cells, regulation of cell growth, apoptosis. |
| Interferon-stimulated gene 20 kDa protein | ISG20 | An exoribonuclease that acts on single-stranded RNA and also has minor activity toward single-stranded DNA. |
| Ubl carboxyl-terminal hydrolase 18 | USP18 | Involved in modulation of the inflammatory response triggered by type I interferons. |
| Proteasome subunit alpha type 3 | PSMA3 | Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. During viral infections mediates apoptosis. |
| Proteasome subunit alpha type 6 | PSMA6 | The same. |
| Proteasome activator complex subunit 2 | PSME2 | Implicated in immunoproteasome assembly and required for efficient antigen processing. |
| Bone marrow stromal antigen 2 | BST2 | Blocks the release of diverse mammalian enveloped viruses by directly tethering nascent virions to the membranes of infected cells. Acts as a direct physical tether, holding virions to the cell membrane and linking virions to each other. |
| Protein                                                             | Gene/protein abbreviation | Functions (abbreviated)                                                                 |
|--------------------------------------------------------------------|---------------------------|----------------------------------------------------------------------------------------|
| Interferon-induced helicase C domain-containing protein 1          | IFIH1                     | Sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines. |
| TRAF-type zinc finger domain-containing protein 1                   | TRAFD1                    | Negative feedback regulator that controls excessive innate immune responses mediated by Toll-like receptor 4 and DDX58/RIG1-like pathways. |
| Vesicle-associated membrane protein 5                              | VAMP5                     | Intracellular trafficking events.                                                      |